Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
15002134094 |
Email: |
marketing@targetmol.cn |
Products Intro: |
Product Name:BVB-808 CAS:1180158-99-9 Package:50mg/RMB 13800;25mg/RMB 10600;100mg/RMB 17500
|
7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel- manufacturers
- BVB-808
-
- $1980.00 / 50mg
-
2024-10-28
- CAS:1180158-99-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel- Basic information |
Product Name: | 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel- | Synonyms: | 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel-;BVB-808 | CAS: | 1180158-99-9 | MF: | C28H32F2N8O | MW: | 534.6 | EINECS: | | Product Categories: | | Mol File: | 1180158-99-9.mol | |
| 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel- Chemical Properties |
Boiling point | 660.0±65.0 °C(Predicted) | density | 1.41±0.1 g/cm3(Predicted) | pka | 8.72±0.60(Predicted) |
| 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel- Usage And Synthesis |
Description | BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML). |
| 7H-Pyrrolo[2,3-d]pyrimidin-2-amine, 7-[3,5-difluoro-4-(4-morpholinylmethyl)phenyl]-N-[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl]-, rel- Preparation Products And Raw materials |
|